obesity
Danish pharmaceutical giant Novo Nordisk has announced a plan to invest $4.1 billion (€3.8 billion) to expand its US manufacturing capacity. The new plant will be a second fill and finishing facility for high-in-demand weight loss drugs like Wegovy and Ozempic in Clayton, North Carolina. Novo Nordisk's decision to invest in the US comes as part of its broader strategy to enhance its global manufacturing network. The medical firm states that: "Marking one of the largest manufacturing investments in Novo Nordisk's history, the expansion will add 1.4 million square feet of production space for as...
Euronews (English)
A popular weight-loss drug may help people who struggle with a serious sleep disorder, according to a new study. Tirzepatide, the medication in the weight-loss drug Zepbound and the diabetes treatment Mounjaro, appeared to reduce the severity of sleep apnoea, according to a new study. The findings were published in the New England Journal of Medicine last week, and included 469 people with obesity and obstructive sleep apnoea (OSA). OSA is a disorder where people stop breathing while they are asleep because the tissue in the throat relaxes and collapses during sleep, fully or partially blockin...
Euronews (English)
The World Health Organization (WHO) has issued a global warning about falsified injections of semaglutide, a blockbuster weight-loss drug that is used to treat obesity and type 2 diabetes. The medical alert concerned three falsified batches of the injection, known by its brand name Ozempic, which was found in Brazil, the UK, and the US in 2023. "WHO advises healthcare professionals, regulatory authorities and the public be aware of these falsified batches of medicines," said Dr Yukiko Nakatani, WHO's assistant director-general for access to medicines and health products. "We call on stakeholde...
Euronews (English)
Menstrual periods may be starting earlier in younger generations, according to new research. The study was published on Wednesday in the scientific journal JAMA Network Open and based on data from the Apple Women’s Health Study, which involved 71,341 women. Researchers in the US found that the average age at which girls begin menstruating has decreased from 12.5 years for those born between 1950 and 1969 to 11.9 years for those born between 2000 and 2005. There has also been an increase in the time it takes for menstrual cycles to become regular after menarche (the first menstrual cycle), with...
Euronews (English)
For more than a year, there has been a rising trend in using diabetes drugs such as Ozempic solely for its weight loss effect. As with any medication, there are potential risks of side effects that you may or may not have been aware of initially. For instance, in 2023, American Jaclyn Bjorklund launched legal proceedings against Novo Nordisk and Eli Lilly and Co, the manufacturers of Ozempic and Mounjaro respectively, alleging severe gastrointestinal complications, particularly gastroparesis characterised by a paralysis of the stomach. Ozempic: How a TikTok weight loss trend caused a global di...
Euronews (English)
The weight-loss drug semaglutide - commonly sold under the brand names Ozempic and Wegovy - reduced cardiovascular events such as stroke and heart attack in adults with preexisting disease independent of weight loss. It also helped people keep their weight down for at least four years. That is according to two new analyses of a large trial presented at the European Congress on Obesity in Venice on Monday. Semaglutide is the main active ingredient in the popular weight-loss jabs Ozempic and Wegovy. It mimics the GLP-1 hormone which can signal that your body is full. The analyses looked at the S...
Euronews (English)
Nestlé’s baby food products sold in low and middle-income countries contain unhealthy levels of sugar, found an investigation by Swiss NGO Public Eye and the International Baby Food Action Network (IBFAN). What’s more, while the food giant abides by marketing restrictions in Europe, it also “takes advantage of the weakness of existing regulations” in lower and mid-income countries, the probe found. Researchers examined about 150 products and found in many cases that the same baby formula with no added sugar in Switzerland, Germany, France, and the UK, contained unhealthy levels of it in countr...
Euronews (English)
Washington (AFP) - The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage. Wegovy, produced by Danish pharmaceutical giant Novo Nordisk, was approved "to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight," the FDA said in a statement. The FDA's decision could be a game changer for the approximately 70 percent of American adults who it says are either obese or ...
AFP
Washington (AFP) - Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity. "I would work out sometimes three times a day, I was doing hours worth of classes. I was eating really, really clean… and nothing was changing" the 36-year-old esthetician told AFP in a recent interview. "I heard about Ozempic for a while and then you start to see other people doing it like celebrities and then dropping weight super fast," she said. Fearing gastrointestinal iss...
AFP
Washington (AFP) - The US Food and Drug Administration (FDA) on Wednesday announced it had approved Eli Lilly's highly anticipated weight loss drug Zepbound, the latest entrant in a field of powerful -- and lucrative -- new obesity medicines. It is expected to be available in the United States within weeks, joining the likes of Novo Nordisk's successful Ozempic and Wegovy, and is widely expected to become a bestseller. JPMorgan analysts have predicted annual sales for so-called GLP-1 drugs to reach $140 billion by 2032, with the market dominated by Novo and Lilly. Administered by weekly injec...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら